Remove 2026 Remove Health Remove Joints
article thumbnail

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoSpineNews

. “The anatomical design of the implant restores the normal stabilization and cushioning functions of the meniscus to relieve symptoms and preserve knee joint health.” ” OrthoPreserve hopes to launch their Pilot clinical trial in 2026, while aiming for potential FDA approval by 2029. About OrthoPreserve, Inc.

article thumbnail

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28

OrthoSpineNews

if net sales are between $346 million and $361 million) during Zimmer Biomet’s fiscal year 2026. Established in 2010, Paragon 28 has an extensive suite of surgical offerings and product systems spanning all major foot and ankle segments, including fracture and trauma, deformity correction and joint replacement.